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Augmented renal clearance (ARC) observed in the critically ill pediatric population has
received an increased attention over the last years due to its major impact on the
disposition and pharmacokinetics of mainly renally excreted drugs. Apart from an
important inflammatory trigger, fluid administration has been suggested to contribute
to the development of ARC. Therefore, the primary objective of this study was to evaluate
the effect of continuous intravenous fluid administration on renal function using a
conventional piglet animal model and to quantify the impact of fluid administration on
the pharmacokinetics of renally excreted drugs. At baseline, twenty-four piglets (12
treatment/12 control; 7 weeks old, all _) received the marker drugs iohexol
(64.7 mg/kg body weight (BW)) and para-aminohippuric acid (10 mg/kg BW) to
quantify glomerular filtration rate and effective renal plasma flow, respectively. In
addition, the hydrophilic antibiotic amikacin (7.5 mg/kg BW) was administered.
Following this baseline measurement, the treatment group received fluid therapy as a
constant rate infusion of 0.9% saline at 6 mL/kg/h over 36 h. After 24 h of fluid
administration, the marker drugs and amikacin were administered again. When
comparing both groups, a significant effect of fluid administration on the total body
clearances of iohexol (p  0.032) and amikacin (p  0.0014) was observed.
Clearances of iohexol and amikacin increased with on average 15 and 14%, although
large interindividual variability was observed. This led to decreased systemic exposure to
amikacin, which was manifested as decrease in area under the plasma concentration-time
curve from time 0 h to infinity from 34,807 to 30,804 ng.h/mL. These results suggest that
fluid therapy is a key factor involved in the development of ARC and should be taken into
account when administering mainly renally excreted drugs. However, further research is
necessary to confirm these results in children.
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INTRODUCTION
Intravenous (IV) fluids are often administered to hospitalized
pediatric patients. Generally, fluid therapy is provided either to
replace ongoing losses of water and electrolytes under normal
physiological conditions, also known as maintenance therapy, or
to correct for any existing electrolyte and water deficits, known as
fluid resuscitation (Sterns, 2019). Guidelines are available to guide
the volume and type of administered fluid; however they are not
always unequivocal and remain subject of extensive debate (Perel
et al., 2013; Lira and Pinsky, 2014; Padua et al., 2015; Feld et al.,
2018; National Institute for Health and Care Excellence, 2020). IV
fluid administration is undoubtedly no exact science.
Determining the optimal volume, administration rate, and
composition of IV fluids can be a difficult task. Consequently,
errors in prescribing fluid therapy are not uncommon.
Detrimental effects have been associated with both excessive
and too limited IV fluid administration (Hilton et al., 2008;
Hopf and Morrissey, 2019). Too much fluid is associated with
complications such as tissue edema and poor cardiac function,
whereas too little fluid may lead to inadequate tissue perfusion
and impaired wound healing (Hopf and Morrissey, 2019).
Furthermore, the administration of IV fluids is thought to
contribute to the development of augmented renal clearance
(ARC) (Udy et al., 2010). ARC refers to a supraphysiological
state of the kidney and is characterized by an increased
elimination of circulating solutes compared to normal
baseline (De Waele et al., 2015; Wu et al., 2016). This is
particularly relevant for critically ill patients, where ARC
may lead to subtherapeutic plasma concentrations of mainly
renally excreted drugs, such as aminoglycosides and ß-lactam
antibiotics. Consequently, ARC may negatively affect the
patient’s clinical outcome. ARC is a well described
phenomenon in the critically ill adult patient population but
evidence on its occurrence in critically ill children is
accumulating as well (De Cock et al., 2015; Van der Heggen
et al., 2019). A recent study of Van Der Heggen et al.
demonstrated a high prevalence of ARC (67%) in critically ill
children (Van der Heggen et al., 2019). Despite the hypothesis
that fluid therapy can contribute to ARC, the volume of
administered fluid is not consistently identified as risk factor
for development of ARC (Udy et al., 2010; Campassi et al., 2014;
Declercq et al., 2016; Hirai et al., 2016; Cook and Hatton-
Kolpek, 2019; Van der Heggen et al., 2019). Furthermore,
limited data are available on the effect of continuous IV fluid
administration on the renal function. Leake et al. observed in
infants weighing less than 2 kg a higher inulin clearance when
infusing fluid at a high rate (10.3 mL/kg/h) compared to a low
rate (3.6 mL/kg/h). Conversely, in children weighing more than
2 kg, inulin clearance did not significantly increase when
administering fluid at hight rate (Leake et al., 1976). Also,
inconsistent results about the glomerular response to IV
bolus administered saline are reported in humans (Crawford
and Ludemann, 1951a; Stenvinkel et al., 1992; Hahn et al., 2016).
Due to their resemblance with humans with respect to size,
anatomy, and physiology of the kidney and other organ systems,
pigs could be an appropriate animal model to study the
underlying mechanism of ARC, the contribution of fluid
administration to the development of ARC, and the effect of
ARC on the pharmacokinetics (PK) of renally excreted
antimicrobials (Gasthuys et al., 2016). Previously, Gasthuys
et al. demonstrated that the maturation of the glomerular
filtration rate (GFR) was comparable in humans and
conventional pigs, making the piglet a potential good
preclinical model for pediatric drug research (Gasthuys et al.,
2017a). Furthermore, we recently demonstrated that mature
values of GFR, effective renal plasma flow (ERPF), anion
secretion, and tubular reabsorption were in the same order in
humans and conventional pigs (Dhondt et al., 2020).
The primary aim of the current study is to investigate the effect
of a constant rate infusion (CRI) of 0.9% saline on glomerular
filtration and renal plasma flow, using the conventional pig as
animal model. Due to the high prevalence of ARC in the pediatric
population, it was decided to perform this study in juvenile pigs
(Udy et al., 2014; De Waele et al., 2015; Mulder et al., 2019; Van
der Heggen et al., 2019). The fluid rate was chosen as such that the
fluid requirements of piglets were moderately overestimated,
mimicking a condition of moderate extensive fluid
administration in children. The renal function was evaluated
using iohexol and para-aminohippuric acid as markers.
Furthermore, it was evaluated if fluid administration alters the
PK of renally cleared drugs using amikacin as a test compound. In
addition, it was investigated whether amikacin clearance could
serve as an estimate for the GFR.
MATERIALS AND METHODS
Animals
The current study was conducted with consent of the Ethical
Committee of the Faculty of Veterinary Medicine and the Faculty
of Bioscience Engineering of Ghent University (EC 2017/24).
Care and use of animals were in full compliance with the Belgian
(Anonymous, 2013) and European legislation on animal welfare
and ethics (2010/63/EU) (The European Parliament and the
Council of the European Union, 2010; Anonymous, 2013).
Twenty-four clinically healthy, 6-week-old male piglets
(Landrace x Large White, Seghers Hybrid®, RA-SE Genetics,
Belgium) were recruited for this study. Due to practical issues,
the trial was divided over three different time periods spread over
three months. Piglets were equally handled over these periods. In
each period, eight piglets were randomly divided over treatment and
control group. Upon arrival, piglets were group-housed (4 piglets
per pen) in standard pig pens (2.30 × 2.40m) with ad libitum access
to water and feed (Piggistart Opti®, Aveve, Leuven, Belgium).
During the entire experimental period, stables were enriched
with rubber toys, balls of different size, and cotton towels. After
a 5-day acclimatization period, a double-lumen jugular catheter was
surgically inserted following the procedure described by Gasthuys
et al., permitting IV infusion and blood collection (Gasthuys et al.,
2017b). To allow urine collection, a human stoma ring (Esteem
synergy® Uro, 48mm, ConvaTec, Braine-l’Alleud, Belgium) was
attached around the prepuce of the piglets during anesthesia
(Gasthuys et al., 2017b). After surgery, the piglets were housed
Frontiers in Pharmacology | www.frontiersin.org January 2021 | Volume 11 | Article 6071012
Dhondt et al. Contribution of Fluid to ARC
individually to avoid displacement of the catheters and stoma rings.
Catheters were flushed twice daily with heparinized 0.9% saline (50
IU/mL) and the bandages were changed daily. Natural light was
provided by translucent windows. The mean (± standard deviation
(SD)) stable temperature was 24.7 ± 0.99 °C. Body temperature was
measured twice daily using a Biothermo Lifechip (Allflex, Vitré,
France), placed in themusculus gluteus maximus during surgery. All
piglets were weighed prior to surgery and the day before drug or
fluid administration.
Trial Design
A graphical illustration of the conducted trial is shown in
Figure 1. The piglets were allowed to recover for one day after
surgery. The following day (Day 0), baseline measurements were
performed (measurement 1 or M1). All piglets (7 weeks old,
14.1 ± 1.6 kg body weight (BW), fasted for 10 h) received single,
consecutive IV boluses of iohexol [64.7 mg/kg BW, Omnipaque
300® (GE Healthcare, Eindhoven, The Netherlands)], para-
aminohippuric acid (PAH, 10 mg/kg BW), and amikacin
(7.5 mg per kg BW, Amukin® 1g/4 mL, S.A. Bristol-Myers
Squibb, Brussels, Belgium) using the proximal lumen of the
jugular catheter. The commercially available analytical
standard of sodium PAH, purchased from Sigma-Aldrich
(Bornem, Belgium), was prior to administration dissolved in
0.9% saline solution at a final concentration of 100 mg/mL
PAH. After administration, venous blood samples (1.5 mL)
were collected from the distal lumen of the catheter into K3-
EDTA collection tubes (Vacutest Kima®, Piove di Sacco, Italy) at
0 (prior to administration), 5, 10, 20, 30, 45, and 60 min and 1.5,
2, 4, 6, 8, and 10 h after administration (p.a.) and immediately
stored on ice. Samples were centrifuged (2,095 x g, 10 min, 4 °C)
within 2 h and aliquots of plasma were stored at ≤ −80 °C until
analysis. Urine bags were emptied regularly. At each collection
point, the collected volume was noted and an aliquot for analysis
was taken. Urine samples were stored at ≤−15 °C. Since
inflammation is considered a major trigger of ARC, a total
white blood cell count and formula were performed before
administration of the drugs to rule out the presence of
inflammation and/or infection. These measurements were
performed by Medvet BVBA clinical laboratory (Antwerp,
Belgium). Piglets demonstrating an extreme deviation in
hematology values in combination with an elevation in body
temperature were excluded from the study. During this baseline
measurement all piglets received ad libitum water. Feed was
provided 4 h p. a. Thereafter, the piglets could recover for 2 days.
The third day after the baseline measurement (Day 3), fluid
administration was started in twelve piglets (treatment group).
The piglets received 0.9% saline as a CRI at 6 mL/kg/h for 36 h,
administered via the proximal lumen of the catheter. In contrast
to the untreated piglets (control group), to which ad libitumwater
was provided, these piglets had no additional access to water.
Twenty-four hours after the start of the infusion, the same drugs
as during the baseline measurement were administered to the
animals (16.1 ± 1.8 kg, fasted for 10 h) (M2). Blood sampling and
sample handling were performed the same way as described
above. Again, an additional sample was taken for total white
blood cell count and formula. Before and after 12, 24, and 36 h of
fluid administration a blood sample was taken to assess
hematocrit levels. Hematocrit was measured by Medvet BVBA
(Antwerp, Belgium).
Bioanalysis Method of Iohexol,
Para-Aminohippuric Acid, and Amikacin in
Plasma and of Para-Aminohippuric Acid in
Urine
Total plasma iohexol and PAH concentrations were quantified
simultaneously using an ultra-high performance liquid
chromatography-tandem mass spectrometry (UHPLC-MS/MS)
method previously described by Dhondt et al. (2019) with minor
modifications (Dhondt et al., 2019). More specifically, a
13C-labeled IS for PAH analysis (13C6-PAH, Alsachim, Illkirch
FIGURE 1 | Graphical illustration of the trial design including in total 24 piglets. After placement of a jugular catheter, baseline pharmacokinetics (PK) were
determined of iohexol (64.7 mg/kg BW), PAH (10 mg/kg BW), and amikacin (7.5 mg/kg BW). After a two-day rest, fluid at a rate of 6 mL/kg/h of 0.9% saline was
administered over 36 h to 12 piglets (treatment group). After 24 h of fluid administration, the PK determination of the above mentioned drugs was repeated in both the
fluid treated (n  12) and the control (n  12) piglets.
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Graffenstaden, France) was employed instead of para-
aminobenzoic acid. The lower limit of quantification (LLOQ)
was 0.25 μg/mL for both compounds. The same UHPLC method
was used for analysis of PAH in urine samples. Information about
the applied sample preparation as well as validation results are
presented in the Supplementary Material. The LLOQ of PAH
quantification in urine was 0.25 μg/mL.
Plasma concentrations of amikacin were quantified using an
in-house validated UHPLC-MS/MS method. The LLOQ was set
at 0.50 μg/mL. A broad method description and validation results
are provided in the Supplementary Material section.
Pharmacokinetic Modeling
Pharmacokinetic modeling of the plasma concentration-time
data was performed using Phoenix® 8.1 (Certara, USA).
Values below the LLOQ were excluded from the dataset. This
resulted in percentages of extrapolated area under the curve
(AUC) of less than 10% for each compound. The PK models
were fit to each individual concentration-time profile. The
structural model for amikacin was a two-compartmental
model with first-order elimination. A multiplicative error
model was used. For iohexol and PAH, the plasma
concentration-time data was best described by a two-
compartmental model with first-order elimination and a
multiplicative residual error model. However, in six out of 48
iohexol PK measurements (from five different piglets) and nine
out of 48 PAH PK measurements (from eight different pigs), a
two-compartmental model with multiplicative error model failed
to describe the data appropriately. This resulted in an
unacceptable precision of the individual PK parameter
estimations, as reported by the coefficient of variation (CV%).
For those measurements, the profile was better described by a
one-compartmental model with first-order elimination, which
resulted in acceptable CV%. In those cases, a multiplicative error
model was used for iohexol, whereas an additive error model was
used in case of PAH. The estimated primary parameters were
volume of distribution (Vd) and total body clearance (CLTOT).
Also the following secondary variables were calculated: volume of
distribution at steady state (Vss) and the area under the curve
from time 0 h to infinity (AUC0→inf).
The cumulative amount of unchanged compound recovered in
the urine (Ae) was calculated taking the sum of the amount
excreted at every collection point. This amount was calculated by
multiplying the observed concentration by the volume collected
at every collection point. Subsequently, the renal clearance (CLR)
of PAH, which was used to evaluate the ERPF, was calculated by
following formula:
CLR  AeAUC0→ inf
The total body clearance of iohexol was used for the
determination of the GFR.
The percentage change in plasma volume was calculated from
the hematocrit value under the assumption of constant red cell







with H1 the hematocrit value before fluid administration and H2
the hematocrit value at 12, 24, or 36 h after the start of the fluid
administration.
Statistical Analysis
Statistical analyses were performed using Rstudio version 3.6.1
and Prism GraphPad version 6.01. To evaluate if enhanced
clearances were present at M2 within each group, a one-sided
Wilcoxon signed rank test was performed. A one-sided Mann-
Whitney U test was used, to assess if the increases in clearance
were more pronounced in the treatment than in the control
group. To evaluate the effect of fluid administration on Vss,
AUC0→inf and urine output two-sided tests were performed.
Changes in body temperature and white blood cell count
within each group were evaluated using a two-sided Wilcoxon
signed rank test, whereas differences in change in body
temperature between groups were assessed using a Mann-
Whitney U test. The level of significance was set at 0.05.
Median (25th percentile-75th percentile) is presented.
Correlations were determined using a Pearson correlation test.
To assess the agreement between two measurements in the
control group, Bland-Altman plots were plotted. To evaluate
changes in hematocrit over time a linear regression analysis
was performed. In order to evaluate differences in plasma
volume changes, a general linear model with time as within-
subject factor and group as between-subject factor was used. To
evaluate changes in plasma volume between groups at every time
point, a Mann-Whitney U test was performed.
Coefficients of variation (CV%) were calculated for repeated
measurements by dividing the standard deviation by the mean of
the measurements. The reproducibility (R) of the clearance
measurements was calculated as a mean coefficient of






where CVi is the coefficient of variation in subject i for duplicate
determinations and n is the number of subjects (Gaspari et al.,
1998). The calculated reproducibility in this study accounted for
both methodological and biological variations.
RESULTS
Hematology and Body Temperature
In all piglets, a double lumen jugular catheter was inserted
successfully. These were functional throughout the whole
study period. During the trial, the piglets showed normal
activity and appetite. No adverse effects were observed during
the constant rate infusion of 0.9% saline. Figure 2 shows the
leukocyte (A), neutrophil (B), lymphocyte (C), and monocyte (D)
count in the control and treatment group determined just before
baseline measurement (M1) and before the second
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administration of drugs (M2). In one piglet (control group, third
period), a substantial elevated leukocyte count (32,690/µL)
against normal reference range (11,300–22,800/µL) was
observed around the time of second administration of the
drugs. This was mainly attributed to an increase in neutrophil
count (23,341/µL, normal reference range: 3,100–9,600/µL) as
shown in Figure 2B. Simultaneously, an increase of 1.2 °C in body
temperature against the baseline measurement was observed.
Therefore, it was decided to exclude this piglet in the further
calculations. After exclusion of this piglet, no significant
differences in leukocyte (control: p  0.29; treatment: p 
0.39), neutrophil (control: p  0.08; treatment: p  0.39), and
lymphocyte count (control: p  0.59; treatment: p  0.75) were
observed between the first and second measurement within each
group. Monocyte counts were in both groups significantly
decreased at the second evaluation (control: p  0.03; treatment:
p  0.02; Figure 2D). Nevertheless, 87% of the values were within
the reference interval (300–1,200/µL). Also, the outlier in
monocyte count (1,144/µL), observed at second measurement in
the treatment group, was still within this reference interval
(Figure 2D). An outlier in lymphocyte count was observed in a
control piglet at first measurement (Figure 2C). Nevertheless, this
increased lymphocyte count was not accompanied by a deviation in
body temperature (39.2 °C), nor abnormal behavior. Therefore, this
piglet was not excluded from the dataset. In Figure 3, boxplots of
the body temperature measured before the administration of drugs
in the control (n  11) and treatment group (n  12) are shown. No
statistically significant differences in body temperature were
observed between the two measurements within the control
(p  0.66) and treatment group (p  0.91) and between groups
(p  0.69).
Effect of Fluid Administration on PK
Parameters of Iohexol, Para-Aminohippuric
Acid, and Amikacin
In Table 1 the PK parameter estimates of iohexol, PAH, and
amikacin are presented. For all three compounds, a significant
effect of fluid administration on the total body clearance of the
drugs was observed within the treatment group. For iohexol, an
average increase of 15% (range: −5 to + 45%) in total body
clearance was observed after fluid administration, whereas in the
control group the average increase was limited to 2% (range: −10
to +26%). The latter highlights the reproducibility of the iohexol
measurement (R  5.81%) in piglets (Table 2). In the control
group, repeated measurements of GFR with iohexol resulted in
individual differences of less than 10% between the two
measurements in 10 out of 11 piglets, as illustrated in
Figure 4A. In one control piglet an unexpected increase in
iohexol clearance was observed. A possible explanation could
FIGURE 2 | Boxplots of leukocyte (A), neutrophil (B), lymphocyte (C), and monocyte (D) count in the control (n  12) and treatment (n  12) group determined just
before baseline measurement (M1) and before the second administration of drugs (M2). The boxplots illustrate the median and 25th and 75th percentiles. The whiskers
extent from the 25th/75th percentile to theminimum/maximum value, respectively, no further than 1.5 times the interquartile range. Outliers, defined as a value exceeding
1.5 the interquartile range, are plotted individually. The deviating values in leukocyte and neutrophil count of the excluded piglet are clearly illustrated as outliers.
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be an upcoming infection since a transient elevation in body
temperature up to 41 °C was observed at 12 h after the start of the
fluid administration. It was decided to not exclude this piglet out
of the data set, since no major deviations in hematology were
observed. Nevertheless, statistical analysis revealed that the
increase in iohexol clearance was significantly higher in the
treated group than in the control group (p  0.032).
Furthermore, the effect of fluid administration on the
clearance of iohexol showed large interindividual differences.
In five out of 12 piglets iohexol clearance during fluid
administration was within −10 to + 10% of the baseline
measurement. In respectively four and one out of 12 piglets an
increase of 10 to 20% and 20 to 30% against baseline was
FIGURE 3 | Boxplot of the body temperature in the control (n  11) and
treatment (n  12) group determined just before baseline measurement (M1)
and before the second administration of drugs (M2). The boxplots illustrate the
median and 25th and 75th percentiles. The whiskers extent from the
25th/75th percentile to the minimum/maximum value, respectively, no further
than 1.5 times the interquartile range. Outliers, defined as a value exceeding
1.5 the interquartile range, are plotted individually.
TABLE 1 | Pharmacokinetic parameters of iohexol (64.7 mg/kg BW), para-aminohippuric acid (PAH, 10 mg/kg BW), and amikacin (7.5 mg/kg BW) after single intravenous
bolus administrations to 7-week-old piglets. In the control group, the baseline and second measurements were performed under identical conditions. In the treatment
group, the second measurement was performed after 24 h fluid administration consisting of 0.9% saline at 6 mL/kg/h constant rate infusion. The median (25th-75th
percentile) is represented.
IOHEXOL
Control group (n = 11) Treatment group (n = 12)
Baseline measurement Measurement 2 Baseline measurement Measurement 2
CLTOT (mL/min/kg)* 3.82 (3.41–4.01) 3.72 (3.41–4.18) 3.55 (3.34–4.33)
† 4.25 (3.88–4.55)
Vss (mL/kg)* 371.65 (366.86–390.63) 383.76 (363.69–392.63) 389.34 (361.79–405.96)
† 412.17 (386.92–444.70)
AUC0→inf (ng.h/mL) 282,347 (268,682–315,970) 289,572 (258,373–315,804) 303,801 (249,314–322,605)
† 253,727 (236,903–277,969)
PAH
Control group (n = 11) Treatment group (n = 12)
Baseline measurement Measurement 2 Baseline measurement Measurement 2
CLTOT (mL/min/kg) 24.25 (21.72–29.15) 26.22 (22.19–29.45) 24.38 (21.37–27.90)
† 25.37 (24.54–31.79)
CLR (mL/min/kg)
Δ 9.62 (8.01–11.32) 12.55 (11.53–15.94) 11.46 (9.60–13.17) 15.53 (13.07–18.26)
Vss (mL/kg) 486.18 (445.81–534.54) 493.82 (409.79–566.10) 486.43 (421.64–556.04)
† 577.24 (530.76–628.57)
AUC0→ inf (ng.h/mL) 6,874 (5,725–7,673) 6,357 (5,660–7,530) 6,843 (5,982–7,808) 6,572 (5,243–6,793)
AMIKACIN
Control group (n = 11) Treatment group (n = 12)
Baseline measurement Measurement 2 Baseline measurement Measurement 2
CLTOT (mL/min/kg)* 3.68 (3.40–4.06) 3.67 (3.12–4.04) 3.59 (3.29–3.98)
† 4.06 (3.82–4.36)
Vss (mL/kg) 510.76 (506.30–521.05)
† 482.45 (432.55–506.83) 523.10 (497.01–565.16) 539.22 (489.56–551.58)
AUC0→inf (ng.h/mL)* 34,000 (30,839–36,830) 34,076 (31,108–40,373) 34,807 (31,420–38,071)
† 30,804 (28,674–32,763)
CLTOT: total body clearance; CLR: renal clearance; Vss: volume of distribution at steady state; AUC0→inf: area under the plasma concentration-time curve from time 0 h to infinity. If no
significant differences were present, no annotations were made.
Significant differences (p < 0.05) in PK parameter between baseline measurement and measurement 2 within each group are annotated with †.
Significant differences in change of a PK parameter (M2-M1) between treatment and control group are indicated with *.
ΔPAH renal clearances were assessed in four pigs per group.
TABLE 2 | Reproducibility of the total body clearance of iohexol, para-
aminohippuric acid (PAH), and amikacin after administration of iohexol
(64.7 mg/kg BW), PAH (10 mg/kg), and amikacin (7.5 mg/kg BW) to 7-week-old
piglets with ad libitum access to water (control group, n  11)).
Parameter Iohexol Amikacin PAH
N 11 11 11
Mean CV (%) 3.64 4.52 13.36
Range of CV (%) 0 to 16 0 to 10 2 to 41
R% 5.81 5.52 18.14
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observed. In two other piglets the increase exceeded 30%, namely
35 and 45%.
Similar results were observed for amikacin. The total body
clearance in the treatment group increased after fluid
administration with on average 14% (range: −5 to +33%). In
contrast, the change in total clearance in the control group
remained limited to −0.06% (range: −13% to 12%). As a
consequence, a good reproducibility (R  5.52%) of the
amikacin clearance was observed, as illustrated in Table 2
and Figure 4B. When comparing the control and treated
group, a statistically significant higher increase in amikacin
clearance was observed after fluid administration (p  0.0014).
Again, interindividual differences were present. In five out of
12 piglets of the treatment group, total amikacin clearance
values during fluid administration increased less than 10%
against baseline measurement. In the +10–+20% and
+20–+30% interval each time three piglets were present.
One piglet showed an increase in amikacin clearance of
more than 30% after fluid administration. When comparing
baseline total iohexol and amikacin clearances a reasonably
good correlation (r  0.794; p < 0.0001; n  23) and agreement
was observed, as illustrated in Figure 5. Also under perturbed,
fluid administration conditions, a good correlation between
iohexol and amikacin clearances was observed (r  0.765; p 
0.004, n  12). In addition, Bland-Altman analysis yielded
similar results. The bias (95% limit of agreements) was 3.14%
(−13.31–19.58%) under fluid therapy (n  12), whereas during
baseline measurements (n  23) a value of 2.98%
(−14.07–20.03%) was obtained.
In comparison with iohexol and amikacin, more variation in
total PAH body clearance was observed after repeated
measurement in the control group, as can be seen in
Figure 4C. This resulted in a lower reproducibility (R 
18.14%) than observed for iohexol and amikacin (Table 2).
Within the control group, no significant increase in total
clearance was observed (p  0.42). Conversely, a significant
increase was observed during fluid administration within the
treatment group (p  0.046). However, there was not enough
FIGURE 4 | Bland-Altman plot of the difference between iohexol (A) total body clearance measurement 1 and measurement 2 vs. the mean of the two
measurements evaluated within the control group (n  11). The difference is expressed as percentages of the values on the axis [(measurement 2—measurement 1)/
mean]. The mean bias is presented as a dashed line. The 95% lower limit of agreement (LLA) and upper limit of agreement (ULA) are presented by dotted lines. Similar
plots were constructed for amikacin (B) and para-aminohippuric acid (C).
FIGURE 5 | Graphical correlation between iohexol (x-axis) and amikacin (y-axis) clearance (A) and Bland-Altman plot of the difference (B) between iohexol and
amikacin total body clearance, expressed as percentages of the values on the axis [(CLIOH–CLAMI)/mean)], vs. the mean of the two clearances, after administration of
iohexol (64.7 mg/kg BW) and amikacin (7.5 mg/kg BW) to 7-week-old piglets with ad libitum access to water. These plots were constructed by using only the baseline
measurements (measurement 1) of each group (n  23). The mean bias is presented as a dashed line. The 95% lower limit of agreement (LLA) and upper limit of
agreement (ULA) are presented by dotted lines.
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statistical evidence to demonstrate that the increase in total body
clearance of PAH was larger in the treatment group than in the
control group (p  0.19).
Regarding the estimation of renal clearance of PAH, only eight
piglets could be included. To evaluate the renal clearance, it is
mandatory to collect urine over the entire period where PAH is
urinary excreted.When a leakage from the urine collection bag was
observed during one of the two renal clearance measurements, the
particular piglet was completely excluded from PAH renal
clearance calculations. Unfortunately, in only eight out of 23
piglets (4 control and 4 treated), urine collection could be
performed twice (M1 and M2) without leakages. No significant
differences were observed between the two measurements within
the control (p  0.31) and treatment group (p  0.063) and between
groups (p  0.44). This observation could be related to the
combination of low sample size, the use of a nonparametric
statistical test, and the limited reproducibility of the PAH clearance.
Concerning Vss, contrasting results were obtained for iohexol,
amikacin, and PAH. In case of iohexol, a significant increase in
Vss during fluid administration was observed within the
treatment group (p  0.008). This increase in Vss was also
significantly higher in the treated than the control group (p 
0.044). For amikacin on the other hand, a significant decrease in
Vss was observed in the control group, when comparing M1 with
M2 (p  9.77 × 10−4). No significant effect on Vss was observed
within the treatment group (p  0.91). For PAH, no significant
changes were observed in Vss within the blank group (p  0.97)
and between groups (p  0.12). In contrast, the increase in Vss
within the treatment group was significant (p  0.021).
Within the treatment group, fluid administration resulted in a
significant decrease in AUC0→inf for iohexol (p  0.012) and
amikacin (p  0.004). For PAH, the decrease was borderline not
significant (p  0.077). In addition, no significant effects in the
control group could be observed for iohexol (p  0.70), amikacin
(p  0.97), and PAH (p  0.97). This resulted in a significant
different change in AUC0→inf when comparing the control and
the treatment group for amikacin (p  0.002). For iohexol, the
change in AUC0→inf was borderline not statistically significant
(p  0.051). In case of PAH, no significant different change was
observed when comparing both groups (p  0.21).
Effect of Fluid Administration on Urine
Output and Hematocrit
Changes in urine output were evaluated in piglets with twice a
complete urine collection. The median (25th percentile-75th
percentile) urine output at baseline measurement was 1.12
(1.08–1.15) and 1.45 (1.25–1.66) mL/kg/h in the control (n 
4) and treatment group (n  4), respectively. In the control group,
the urine output stayed quite constant with a median value of 1.12
(1.06–1.32) mL/kg/h at second measurement. During fluid
administration the urine output in the treated piglets rose to
4.19 (3.95–4.23) mL/kg/h, which corresponded with an average
increase of 185% (range +111% to +241%) against baseline
measurement. Consequently, a significant higher increase in urine
output was observed at second measurement in the treatment group
compared with the control group (p  0.029). In Figure 6 the change
in hematocrit values over time is illustrated.No statistical effect of time
was observed on hematocrit within each group. However, the
percentage change in plasma volume, calculated by the formula of
van Beaumont, differed statistically between groups (p  0.006).
Statistical analysis revealed differences between the groups at 12
(p < 0.001) and 24 h (p  0.02) after the start of fluid
administration. This was primarily caused by a percentage decrease
of plasma volume in the control group (median %ΔP12h: -6.70;
median %ΔP24h:−4.55) rather than an increase in plasma volume
in the treated pigs (median %ΔP12h: 2.99; median %ΔP24h:2.53). No
significant difference was observed after 36 h (p  0.31).
DISCUSSION
To the authors’ knowledge, this is the first study evaluating the
effect of prolonged (36 h), continuous fluid administration on the
renal function in pigs. The rate of saline administration in this
study was based on the porcine water requirements and the daily
amount of IV fluids given to critically ill children admitted to the
intensive care unit (ICU). Since maintenance IV fluid
administration to piglets is no common practice, the rate of
fluid administration during this trial was primarily based on the
oral fluid intake of piglets. Reported porcine daily water intake is
highly variable with values ranging from 1,757 to 2,580 mL for
piglets within the 10–20 kg BW category. This resulted in values,
indexed for BW, of approximately 4.2–7.7 mL/kg/h (Brooks et al.,
1984; Bigelow and Houpt, 1988; SCS Boehringer Ingelheim
Comm. V., 2018). Compared to children within the same
weight category, the fluid requirements of piglets seem slightly
higher. In children, routine maintenance IV fluid rates are
generally determined by the Holliday–Segar formula (Holliday
and Segar, 1957). For infants weighing 3.5–10 and 11–20 kg the
daily fluid requirement is 100 mL/kg or 4.2 mL/kg/h and
1,000 mL plus an additional 50 mL/kg for every kg over 10 kg
BW, respectively. In case of critical illness, fluid requirements
exceed the routine maintenance requirements. In the study of
Van Der Heggen et al., the amount of IV fluids administered to
critically ill pediatric patients ranged between 3.4 and 6 mL/kg/h
(interquartile range) (Van der Heggen et al., 2019). Since the aim
of this study was to evaluate the potential effect of fluid
administration on renal function, a fluid infusion rate of
FIGURE 6 | Variation of hematocrit over time in the control (n  11) and
fluid treated (n  12) group. Mean±SD are presented.
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6 mL/kg/h, which probably slightly overestimates the normal
fluid requirements in piglets, was selected for this study. At
this rate, the volume of administered fluid is approximately
1.5 times greater than the routine maintenance fluid
requirement in children and it approximates the volumes
administrated to critically ill children. In addition, at 6 mL/kg/h
the administered volume is roughly 1.5 times the reported lower
limit of the normal porcine daily water intake. The latter was also
substantiated when taking the porcine water balances reported by
Mroz et al. into account. An increase in urinary output from a
baseline value of 1.46 to 3.99 mL/kg/h, as on average observed in
this study, is related with an increase in (oral) fluid intake from 3.65
to 6.23 mL/kg/h under the assumption that the change in water
consumption is exclusively matched by changes in urine output
(Mroz et al., 1995; Patience, 2012). The underlying calculations are
presented in the Supplementary Material. This observation
confirms that the normal oral fluid requirements in the studied
piglets were exceeded by a factor of roughly 1.7 during IV fluid
administration. Evaluation of the normal oral fluid intake of the
piglets would have had an added value to determine the degree of
overestimation by fluid therapy. However, the stable infrastructure
did not allow accurate measurement of this parameter.
The constant rate infusion of 0.9% saline at a rate of 6mL/kg/h had
a significant effect on the clearance of the administered drugs. The
GFR, measured as the total iohexol clearance, increased with on
average 15%. These results confirm that IV fluid administration
indeed can contribute to the development of ARC. However, in
hospitalized patients, volume of administered fluid was not always
identified as risk factor for developing ARC (Campassi et al., 2014;
Declercq et al., 2016; Hirai et al., 2016; Van der Heggen et al., 2019). A
possible explanation for this discrepancy could be poor recording of
fluid balances in ARC studies by, for example, not taking into account
oral fluid intake or IV fluids concomitantly administered with IV
drugs. Especially in patients admitted to the intensive care unit
considerable amounts of fluid are given concomitantly with the
various administered drugs. Also, the large interindividual
differences in response to fluid administration can be responsible
for the lack of statistical association between fluid administration and
ARC in previous studies. Notwithstanding the presented study was
conducted in relatively strict controlled conditions using healthy
individuals, large interindividual differences in response to fluid
therapy were noted in the studied pigs. Similar or even larger
interindividual variation might be expected in the (critically) ill
pediatric patient population as fluid requirements can be
significantly altered due to the underlying disease state.
Likewise for iohexol, a similar increase in total body clearance
was observed for amikacin. Amikacin is an antibiotic almost
entirely eliminated by glomerular filtration and has been
previously used to quantify developmental changes in GFR in
neonates (De Cock et al., 2012; Zhao et al., 2013). In this study,
amikacin demonstrated a good correlation and agreement with
the measured GFR, determined as iohexol total body clearance.
This indicates that amikacin clearance can be used to quite
accurately evaluate changes in GFR. Furthermore, a high
reproducibility of iohexol and amikacin total body clearance
measurements was observed in the control group, indicating
clearances of both compounds are suitable to evaluate GFR
changes in pigs. In human and dog studies, a similar
reproducibility for iohexol clearances was obtained (Arvidsson
and Hedman, 1990; Gaspari et al., 1998; Finco et al., 2001). The
reproducibility of PAH total body clearance was much lower.
This was partially attributed to two extreme increases in CLTOT of
PAH at second measurement in the control group, as illustrated
in Figure 4C. Additionally, the control piglet demonstrating the
highest increase in PAH clearance corresponds to the piglet with
the highest deviation during repeated iohexol clearance
determination. As a consequence, there was a lack of statistical
evidence to demonstrate that the increase in total PAH clearance
was higher in the treatment group compared to the control group.
Nevertheless, a significant effect of fluid administration on the
total PAH clearance was observed within the treatment group
(p  0.046). Since the two control piglets with an extreme increase
in CLTOT of PAH were also included in the calculations for renal
PAH clearances, no significant effect on this parameter was
observed. Nevertheless, in the treatment group individual
values of CLR of PAH increased with 33–49% from baseline
value after fluid administration. Yet, this observation should be
interpreted with care, since too little information is available to be
conclusive about the reproducibility of ERPF determinations.
Numerous drugs are mainly excreted by the kidney and
therefore their PK can be affected by ARC. In this study,
amikacin was selected as model drug to evaluate the effect of
fluid administration on the PK. Besides the total clearance, also
the AUC0→inf of amikacin was significantly affected by fluid
administration. Consequently, the clinical efficacy of this
compound can be altered. Indeed, the AUC/MIC ratio is
proposed to be an indicator of bacterial killing and clinical
efficacy of aminoglycosides (Bland et al., 2018). In
concordance with that, also other antibiotics with AUC/MIC
as PK/PD indicator of clinical efficacy can be negatively affected
by extensive fluid therapy. Though it is important to mention
that, in concordance with amikacin and iohexol total body
clearances, large interindividual variation in effect of fluid
administration on AUC0→inf was observed. Whereas for some
pigs amikacin AUC0→inf was reduced with 20–30% under
influence of fluid therapy, in other pigs, receiving equal fluid
rates, no or negligible effects on drug exposure were noticed.
Since the effect of fluid administration on drug exposure is not
consistent, the treatment implication varies between patients.
Therapeutic drug monitoring would allow the identification of
patients negatively impacted by fluid administration.
No significant change in hematocrit over time was observed in
either the treatment (p  0.91) or the control group (p  0.69),
indicating no major plasma expansion was present. In contrast, a
decrease in hematocrit was previously observed in case of IV fluid
administration as bolus (Crawford and Ludemann, 1951a). In the
presented study, a significant difference in change in plasma
volume between the groups was observed at 12 and 24 h after the
start of the fluid administration. This effect rather contributed to
a decrease in plasma volume in the control group than an increase
in the treatment group. An explanation for this observation is
lacking but is in accordance with the observed decline in Vss of
amikacin in the control group. In contrast to amikacin, iohexol
showed a slight but significant increase in Vss after fluid
Frontiers in Pharmacology | www.frontiersin.org January 2021 | Volume 11 | Article 6071019
Dhondt et al. Contribution of Fluid to ARC
administration (p  0.008). Iohexol has previously been used as
marker for the assessment of the extracellular fluid (ECF) volume
(Zdolsek et al., 2005; Finch et al., 2015). The volume of distribution
of iohexol is hereby used as an indicator of the ECF volume. Based
on the changes in Vss indexed for body weight, it can be concluded
that there was a significant increase in ECF volume within the
treatment group. Nevertheless, this increase was limited to a
median value of 8% (+2 – +17%). Within the control group the
change in ECF was negligible [0% (−3 – +2%)].
Generally, it is believed that the GFR is stable or will increase
following plasma volume expansion with saline (Burg, 1981;
Stenvinkel et al., 1992). Yet, studies evaluating the renal effects
of IV administered fluids in children are scare. To the authors’
knowledge, only Leake et al. evaluated the renal response to
intravenous infusions in pediatric patients (Leake et al., 1976).
Also in adults, limited studies are available about the implications
of IV fluid administration on the renal function. Most of these
studies evaluate the effect of IV bolus administered saline on the
glomerular response (Crawford and Ludemann, 1951b;
Stenvinkel et al., 1992; Hahn et al., 2016). Between these
studies, highly variable results are reported. According to
Smith et al. the human variability and limited response to IV
bolus saline is species-specific, since more pronounced and
uniform effects are observed in dogs and rats. This could be
attributed to a greater glomerular stability in man than dog/rat or
the presence of currently unidentified factors in its regulation that
are less important for other species (Smith, 1964). In addition,
other factors, such as age and disease state, contribute most likely
to the reported variability in human renal response to fluid
administration. In contrast to bolus IV fluid administration,
studies evaluating in-depth the renal effects of long-term
continuously administered fluids in both children and adults
are currently lacking. The results, presented in this porcine study,
indicate that continuously administered fluids may contribute to
the development of ARC. Nevertheless, it is mandatory to
confirm this effect in the human population. In addition,
further research is necessary to determine the contribution of
fluid therapy to the development ARC under (critically) ill
conditions.
This study had some limitations. First, the white blood cell
count and formula in combination with fever were used to
evaluate the presence of infection/inflammation. These
evaluation criteria might have a limited sensitivity and
specificity in the detection of infection/inflammation in the
studied pigs. Secondly, only one type of fluid (0.9% saline)
and administration rate (6 mL/kg/h) was evaluated. The
response to other commonly applied IV fluid types and other
rates may differ from the one observed in this study.
CONCLUSION
In conclusion, both the total body clearance of iohexol, which is a
measure of the GFR, and amikacin clearance were increased
during the CRI of 0.9% saline at 6 mL/kg/h over 36 h, indicating a
possible contribution of fluid therapy to the development of ARC.
Furthermore, amikacin clearance showed good agreement and
correlation with iohexol clearance. Consequently, this compound
can be used to evaluate the GFR. Due to the increased clearance,
the AUC0→inf of amikacin decreased significantly, which
illustrates the potential impact of fluid administration on drug
PK and potential drug efficacy. Further research is necessary to
confirm these results in humans.
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